In male-to-female trans-sexuals in whom the hormonal treatment has not resulted in sufficient growth of the breasts, augmentation mammaplasty may be considered. Mammaplasty is performed in two-thirds of our patients who have had vaginoplasties. We present our experience of 201 patients operated on at the Academisch Ziekenhuis Vrije Universiteit in Amsterdam up to 1997. The patients' mean age was 34 years (range 17-76) and the mean follow-up was four years (range 2 weeks to 16 years). In keeping with our protocol, most patients had had oestrogen therapy and a successful real-life experience for a minimum of 1.5 years. The mean size of implants has nearly doubled over the years. Male-to-female trans-sexuals often request large breasts and repeated augmentation mammaplasties were required, mainly in cases where the result of initial augmentation was not outspoken.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/028443101300165354 | DOI Listing |
Scand J Plast Reconstr Surg Hand Surg
June 2001
Departments of Plastic and Reconstructive Surgery, Vrije Universiteit, Amsterdam, The Netherlands.
In male-to-female trans-sexuals in whom the hormonal treatment has not resulted in sufficient growth of the breasts, augmentation mammaplasty may be considered. Mammaplasty is performed in two-thirds of our patients who have had vaginoplasties. We present our experience of 201 patients operated on at the Academisch Ziekenhuis Vrije Universiteit in Amsterdam up to 1997.
View Article and Find Full Text PDFEur J Disord Commun
November 1993
Institute of Phonetics, University of Utrecht, The Netherlands.
Utterances were produced in two gender role realizations by male-to-female trans-sexuals. An acoustic analysis of 17 parameters was carried out and results were compared intra-individually. It appears that, in spite of anatomical constraints, subjects were able to realise a number of vocal characteristics that are known to add to a feminine voice quality in the female speaking mode.
View Article and Find Full Text PDFThe present study investigated the effect of administration of somatostatin (SRIF) on the release of prolactin in men. No effect was observed when SRIF was administered to eugonadal men. Release of prolactin was inhibited, however, when SRIF was administered to oestrogen-treated agonadal subjects (male-to-female trans-sexuals) and to an even greater degree when subjects had been pretreated with a combination of oestrogen and cyproterone acetate.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!